

Posters

Cardiology

1. **Atrial septal defect diagnosis in a patient with right-sided heart failure** Anjo C., Satendra M., Victor A.R., Longo S., Parente M.L., Duarte F., Pinto S., Narciso S., Vieira R., Figueiredo H., Lopes S., Bento B., Lousada N., Palma R.R. (Lisbon, Portugal)
2. **MitraClip insertion for severe mitral regurgitation - a case report** Anjo C., Satendra M., Victor A.R., Longo S., Parente M.L., Duarte F., Pinto S., Narciso S., Vieira R., Figueiredo H., Lopes S., Bento B., Lousada N., Palma R.R. (Lisbon, Portugal)
3. **Management of heart failure in an intermediate care unit** Antunes L., Pocinho R., Pires P., Baptista I., Raposo A. (Lisbon, Portugal)
4. **Five years of endocarditis in a tertiary hospital in Portugal** Antunes M., Marques B., Magalhães G., Castro S., Gruner H., Riso N. (Lisbon, Portugal)
5. **Investigation of the relationship between galectin-3 and aortic pulse wave velocity in newly diagnosed type 2 diabetic patients** Arslan E., Demirbaş Ş., Özçelik F., Akhan M., İlhan A., Kılınç A., Taş A., Çaycı T., Sağlam K. (Ankara, Turkey)
6. **The effect of aspirin resistance on graft occlusion after coronary artery bypass grafting** Arslan S., Karaağaç K., Yetkin Z.A., Bilgili G., Albayrak S., Serdar Z., Serdar O.A., Aydınlar A. (Bursa, Turkey)
7. **Severe idiopathic pulmonary hypertension – case presentation** Barbu M., Humulescu C., Gurghean A., Mihailescu A., Spataru D. (Bucharest, Romania)
8. **Self-reported sleep characteristics and cardiovascular diseases: data from the cohort population study ESSE-RF (Russia)** Bochkarev M.V., Sviryaev Y.V., Rotar O.P., Korostovtseva L.S., Artamonova G., Balanova Y., Shalnova S.A., Konradi A.O., Boytsov S.A., Shlyakhto E.V. (St.-Petersburg, Moscow, Russian Federation)
9. **Digitalis intoxication** Bouthour O., Conti L., Roux X., Clemente M., Vogt N., Reny J.-L. (Geneve, Switzerland)
10. **Masked hypertension in organized cohort: prevalence, markers, and heart remodeling** Britov A.N., Platonova E.M., Smirnova M.I., Gorbunov V.M., Eliseeva N.A., Deev A.D., Koshelyaevskaya Y.N. (Moscow, Russian Federation)
11. **Descriptive trial of the activity of hypertension in a district hospital** Carvajal Ronderos E.J., Carrera Bolaños L.C., Urbano Gálvez J.M. (Elvas, Portugal)
12. **Comparison between left ventricular hypertrophy and left axis deviation in hypertension consultation** Carvajal Ronderos E.J., Urbano Gálvez J.M., Carrera Bolaños L.C. (Elvas, Portugal)
13. **Association of cardiovascular risk factors, renin-angiotensin-aldosterone system gene polymorphisms with pregnancy outcomes in women with hypertension** Chulkov V.S., Vereina N.K., Sinitsin S.P., Dolgushina V.F. (Chelyabinsk, Russian Federation)
14. **Insulin resistance and endothelial dysfunction in young patients with arterial hypertension and abdominal obesity** Chulkov V.S., Sumerkina V.A., Chulkov V.S., Telesheva L.F., Vereina N.K. (Chelyabinsk, Russian Federation)

15. **Levosimendan, a clinical case** *Costa L., Araújo I., Marques F., Leitão A., Campos L., Fonseca C.* (Lisbon, Portugal)
16. **Heart and blood, two bonded failures? Prevalence and prognosis of anemia and hematinic factors deficiency in heart failure** *Dantas J., Araujo I., Marques F., Vaz R., Carrasco D., Leitão A., Campos L., Fonseca C.* (Lisbon, Portugal)
17. **Minimally invasive versus standard full sternotomy for cardiac surgery: which is the best choice?** *Del Giglio M., Mikus E., Paris M., Zulueta J.L., Panzavolta M., Turci S., Tripodi A.* (Cotignola, Italy)
18. **Neutrophil to lymphocyte ratio – a novel severity biomarker for patients with heart failure with reduced ejection fraction** *Delcea C., Buzea C.A., Dima A., Popescu R.A., Dobranici M., Daha I., Stanescu C., Breha A., Dan A.R., Baicus C., Dan G.A.* (Bucharest, Romania)
19. **CHA2DS2-VASC and HAS-BLED scales in elderly patients with atrial fibrillation** *Demelo Rodríguez P., Álvarez-Sala de la Cuadra A., De Antonio Antón N., Albiñana Pérez A., Del Toro Cervera J., Álvarez-Sala Walther L.* (Madrid, Spain)
20. **Role of arterial blood gas analysis and of electrocardiogram in the diagnosis of pulmonary embolism in patients with chronic obstructive pulmonary disease** *Dentali F., Arioly D., Di Micco P., Gnerre P., Pierfranceschi M.G., Landini F., La Regina M., Mumoli N., Pieralli F., Pomero F.* (Varese, Italy)
21. **Hypertension secondary to antiangiogenetics: an emerging topic in medical departments** *Destro M., Dognini G.P., Cagnoni F., Colombelli P.L., Panza S., Besozzi A., Barni S.* (Treviglio, Italy)
22. **Thirteen years prognostic significance of electrocardiographic left ventricular hypertrophy in patients with arterial hypertension** *Djordjevic D., Tasic I., Stamenkovic B., Kostic S., Lovic M., Lovic D.* (Niska Banja, Nis, Serbia)
23. **The association between blood pressure components and cognitive functions and cognitive reserve** *Esmailpour S., Seifar F., Ranjbar H., Rezvan P.S., Seifar Z.* (Tabriz, Iran)
24. **Galectin-3 and coronary atherosclerosis in patients with myocardial infarction** *Fedorova N.V., Kashtalap V.V., Hryachkova O.N., Barbarash O.L.* (Kemerovo, Russian Federation)
25. **A broken-heart syndrome mimicking multiple diagnoses of troponin elevation** *Fernandes L., Clérigo V., Rodrigues A., Rocha C., Sargento D., Silva G.* (Lisbon, Portugal)
26. **Pulmonary embolism and inferior vena cava thrombosis in a patient with right atrial thrombosis, a case report** *Fernández Romero I., Pelaez Ballesta A.I., Martínez G.L., Campillo C.T., Paredes R.M., Fenor E.M.* (Lorca, Spain)
27. **Sleep disorders as a risk factor for coronary heart disease and its trends in Russia/Siberia (WHO program “MONICA-psychosocial”)** *Gafarov V.V., Gromova E.A., Gagulin I.V., Panov D.O., Gafarova A.V.* (Novosibirsk, Russian Federation)
28. **Low density lipoprotein subfractional distribution in patients with coronary atherosclerosis estimated by Gensini score** *Gavrilova N.E., Metelskaya V.A., Ozerova I.N., Boytsov S.A.* (Moscow, Russian Federation)

29. **Peculiarities of clinical course and fundamental parameters of patients with acute myocardial infarction with ST segment elevation and hyperuricemia** *Golikova A.A., Stryuk R.I., Sergienko I.V., Kozhukhovskaya O.L.* (Moscow, Russian Federation)
30. **Acute heart failure – a descriptive study in Coltea hospital, Bucharest** *Gurghean A., Barbu M., Vintila A.M., Spataru D., Bruckner I.* (Bucharest, Romania)
31. **Cardiac carcinoid syndrome** *Jimenez-Arjona J., Rubio-Marin P., Gamaza-Chulian S., García-Figueras C.* (Jerez de la Frontera, Spain)
32. **Serum adiponectin and leptin levels and the main components of the metabolic syndrome** *Karimova A.M., Mammaev S.* (Makhachkala, Russian Federation)
33. **Correlation between C-reactive protein levels and progression of non-coronary atherosclerosis 1 year after myocardial infarction** *Kashtalap V.V., Usoltseva E.N., Zikov M.V., Barbarash O.L.* (Kemerovo, Russian Federation)
34. **Daily rhythm of blood pressure and metabolic axes in patients with the 5th stage chronic kidney disease** *Kazakova I.A., Ievlev E.N.* (Izhevsk, Russian Federation)
35. **Brain natriuretic peptide as a prognostic factor in patients with sepsis in the absence of heart failure** *Khoury J., Arow M., Braun E., Neuberger A., Aronson D., Berger G., Azzam Z.S.* (Haifa, Israel)
36. **Suppression of intimal hyperplasia by mesenchymal stem cells in carotid balloon angioplasty** *Kim A.-K., Kim D.-I.* (Seoul, South Korea)
37. **Application of the unified questionnaire for cerebrovascular disease detection in patients with arterial hypertension in outpatient clinic environment** *Kim I.V., Bochkareva E.V., Varakin Yu.Ya., Kokurina E.V.* (Moscow, Russian Federation)
38. **Comorbidity as a risk factor in coronary artery bypass grafting** *Klester E.B., Ivanov O.A., Boldenkov S.V., Paraskyn M.V., Klester K.V.* (Barnaul, Russian Federation)
39. **Comorbidity at patients with chronic heart failure: correlation between etiologic factors, structural and functional features** *Klester E.B., Klester K.V., Babushkin I.E.* (Barnaul, Russian Federation)
40. **Hemorrhagic complications in patients with acute coronary syndrome of different age groups** *Kochergina A.M., Kashtalap V.V., Barbarash O.L.* (Kemerovo, Russian Federation)
41. **Clinical and laboratory predictors of poor outcomes in patients with pulmonary embolism of high and intermediate risk** *Kochmareva E.A., Kokorin V.A., Kokorin I.A., Lebedeva A.Y., Gordeev I.G.* (Moscow, Russian Federation)
42. **Risk factors of long-term complications after myocardial infarction** *Kokorin V.A., Luchinkina E.E., Rusina V.A., Gordeev I.G.* (Moscow, Russian Federation)
43. **Prevalence of metabolic syndrome and its components in urban and rural population of Central Kazakhstan** *Laryushina Ye.M., Turmuchambetova A.A., Turgunova L.G., Bakirova R.E., Koychubekov B.K., Alina A.R., Nildibaeva F.U., Sheryazdanova D.N.* (Karaganda, Kazakhstan)
44. **Red cell distribution width in infective endocarditis** *Lazarev P.V., Kotova E.O., Kiyakbaev G.K., Moiseev V.S.* (Moscow, Russian Federation)

45. **Electrophysiological treatment methods influence on some ventricle asynchronicity indices** *Leshchankina N.Y., Ereemeeva E.N.* (Saransk, Russian Federation)
46. **The influence of metabolic syndrome on the quality of life in patients with acute myocardial infarction with ST segment elevation** *Lovic M., Savic L., Matic D., Lovic D., Djordjevic D., Tasic I., Ostojic M.* (Belgrade, Serbia)
47. **Thromboembolic events in left ventricular non-compaction** *Luís M.M., Mascarenhas J., Quintas J., Dias V.P.* (Vila Nova de Gaia, Portugal)
48. **Ischemic preconditioning phenomenon in medical and preventive schemes in coronary artery disease patients** *Lyamina N.P., Kotelnikova E.A., Lyamina S.V.* (Saratov, Moscow, Russian Federation)
49. **Circulating endothelial cells as marker of endothelial damage in midlife women with masked arterial hypertension** *Lyamina N.P., Lyamina S.V., Nalivaeva A., Senchikhin V.* (Saratov, Moscow, Russian Federation)
50. **Diagnostics of hypertrophic cardiomyopathy with hypertrophy of apical segments** *Malov A.A., Feiskhanova L.I.* (Kazan, Russian Federation)
51. **Waist to height ratio significant to discriminate cardiovascular risk: better than waist circumference?** *Mascarenhas F.M., Carvajal Ronderos E.J., Urbano Gálvez J.M., Carrera Bolaños L.C.* (Elvas, Portugal)
52. **Structural and morphological features of heart failure in chronic kidney disease** *Monakhova I.V., Suvorov A.V., Suslova O.A., Zubeeva G.N., Lazukin V.F., Artifeksova A.A.* (Nizhny Novgorod, Russian Federation)
53. **Aortic paravalvular leak: a relatively rare cause of heart failure** *Oliveira E.A., Santos S.M., Monteiro N.F., Soares M., Silva F., Silva A.M.* (Lisbon, Portugal)
54. **Risk of cardiovascular diseases in women with high activity of rheumatoid arthritis** *Osipova I.V., Starodubova J.N., Sopotova I.V.* (Barnaul, Russian Federation)
55. **Two diseases, one pathology** *Palma Anselmo M., Agostinho J., Gonçalves I., Ministro A., Brito D., Veiga F., Pinto F., Pedro M.M.* (Lisbon, Portugal)
56. **Cardiotoxicity of anticancer treatments: a 10-year experience of an advanced heart failure unit in Portugal** *Petrova M., Louro M., Costa S., Franco F., Pego M.* (Coimbra, Portugal)
57. **Advanced heart failure due to cancer therapy** *Pinto C.M., Gonçalves A.T., Afonso T., Maurício H., Madureira E.* (Bragança, Portugal)
58. **Infective endocarditis due to *Proteus mirabilis* infection** *Polishchuk I., Zamir D., Brodtkin B.* (Beer Sheva, Israel)
59. **Modern preventive technology as a way to preserve the professional longevity of employees in organized team** *Pyrikova N.V., Osipova I.V., Kontsevaya A.V., Zaltzman A.G., Antropova O.N.* (Barnaul, Moscow, Russian Federation)
60. **Economic benefit of the formation of preventive environment in the working team from the perspective of an employer** *Pyrikova N.V., Osipova I.V., Zaltzman A.G., Kontsevaya A.V., Antropova O.N.* (Barnaul, Moscow, Russian Federation)

61. **Takotsubo cardiomyopathy - complications in clinical development** *Rodrigues J.B., Rodrigues A., Sargento D.L., Lousada N., Reis R.P., Silva G.* (Lisbon, Portugal)
62. **Kounis syndrome – allergic angina after oral provocation test with metamizole** *Rodrigues J.B., Rodrigues A., Sargento D.L., Silva G.* (Lisbon, Portugal)
63. **Lipid profile changes in familial hypercholesterolemia patients after their inclusion in the SAFEHEART follow up study** *Rubio-Marín P., Michán A., Alonso R., De Isla L.P., Fuentes-Jiménez F., Muñiz O., Díaz J.L., Andrés R., Hidalgo A.M., Miramontes P., Manjón L., López P.M.* (Jerez de la Frontera, Madrid, Spain)
64. **Cardiac comorbidities in patients admitted in medical intensive care units for non-cardiac entities** *Santos C., Bronze L.* (Covilhã, Portugal)
65. **Analysis of risk factors and structural features of patients with ischemic organ damage without stenosing arteriosclerosis** *Shabalina E.A., Anisenkova A.Y.* (Saint-Petersburg, Sestroretsk, Russian Federation)
66. **Role of different combined genes polymorphism (CYP4F2, VKORC1) on the dosing of phenindion in patients with valvular atrial fibrillation** *Shakhidzhanova V.S., Sychev D.A., Kazakov R.E., Grishenko N.D., Palamarchuk Yu.Yu., Tretyakov A.Yu.* (Moscow, Belgorod, Russian Federation)
67. **The correlation of uric acid levels with the occurrence of atrial fibrillation in patients with metabolic syndrome** *Siliste R.N., Caldararu M., Chitroceanu A., Ianula R.M., Isacoff D.* (Bucharest, Romania)
68. **Diastolic heart failure – the enigma** *Simões A.F., Rodrigues J.B., Lopes S., Úria S., Sargento L., Reis R.P., Silva G.* (Lisbon, Portugal)
69. **Survival of patients with congestive heart failure in the representative sample of Ryazan region** *Smirnova E.A., Yakushin S.S., Vorobyev A.N.* (Ryazan, Russian Federation)
70. **A snapshot of blood pressure measurements in hospitalized patients: a missed opportunity for targeted intervention?** *Smyth H., Angelov D., Shiels P.* (Tullamore, Ireland)
71. **Protein binding fatty acids in diagnosis of acute myocardial infarction (GIANT trial)** *Spassky A.A., Kokorin V.A., Mikhaylov A.A., Eremina Yu.N.* (Moscow, Russian Federation)
72. **Influence of complex therapy with mexicor on restoration of coronary function in patients with myocardial infarction** *Spassky A.A., Mikhaylov A.A., Eremina Yu.N.* (Moscow, Russian Federation)
73. **FAR NHL – FARmacology and NeuroHumoraL activation in heart failure registry** *Spinar J., Ludka O., Labrova L., Soucek M., Spinarova L.* (Brno, Czech Republic)
74. **From trivial to intricate** *Stan A.A., Sirbu I.V.* (Targu-Mures, Romania)
75. **Pericardial thickening: one single clue, several differential diagnoses** *Staring G., Amaral B., Costa W., Monteiro F., Barracha I., Amorim R.* (Torres Vedras, Portugal)
76. **Non valvular atrial fibrillation at the department of internal medicine** *Suki M., Elis A.* (Petach Tikva, Israel)

77. **Arterial hypertension relevance in a Portuguese active population in Portugal. Elvas study** *Urbano Gálvez J.M., Carvajal Ronderos E.J., Mascarenhas F.M., Carrera Bolaños L.C.* (Elvas, Portugal)
78. **Prevalence of cardiovascular risk factors in a Portuguese rural area. Elvas study** *Urbano Gálvez J.M., Carvajal Ronderos E.J., Mascarenhas F.M., Carrera Bolaños L.C.* (Elvas, Portugal)
79. **Non-using of beta-blockers as a predictor of unfavorable cardiovascular events among heart failure patients** *Vaiman A.E., Gazizianova V.M., Boulashova O.V., Khazova E.V., Malkova M.I.* (Kazan, Russian Federation)
80. **The factors influencing effectiveness of different teaching methods in heart failure patients** *Vatutin M., Yeshchenko Y.* (Donetsk, Ukraine)
81. **Triglycerides in patients with acute coronary syndrome: clinical significance and risk for readmission** *Venevtseva Y.L., Melnikov A., Gomova T., Fedotova E., Kazidaeva E.* (Tula, Russian Federation)
82. **Relative lymphocyte count: a prognostic indicator of stress response in patients with acute coronary syndrome** *Venevtseva Y.L., Melnikov A., Zotova A., Kazidaeva E., Tsarev N.N.* (Tula, Russian Federation)
83. **A cardiac pleural effusion: is pacemaker insertion an innocuous procedure?** *Vilaça H., Brito A., Rey A., Serôdio J., Costa L., Morgado M., Alves A.M., Brandão A.P.* (Ponte de Lima, Portugal)
84. **Prevention of affective disorders in cardiovascular patients** *Zakharova O., Polunina A., Zakharov E.* (Moscow, Russian Federation)
85. **Vascular endothelial growth factor-D mediates fibrogenic response in myofibroblasts** *Zhao T., Zhao W., Meng W., Liu C., Chen Y., Bhattacharya S.K., Sun Y.* (Memphis, USA)
86. **Acute myocarditis: case report** *Zimmermann N. de A., Dadan Perini L., Prada P., Ferreira L., Ramos de Lima e Silva M., Alberton J., Peluso Alba G.* (Blumenau, Brazil)